Small fiber neuropathy as a complication of SARS-CoV-2 vaccinations.
Adverse reaction
COVID-19
SARS-CoV-2
neuropathy
pain
side effect
small fibers
vaccination
Journal
Journal of family medicine and primary care
ISSN: 2249-4863
Titre abrégé: J Family Med Prim Care
Pays: India
ID NLM: 101610082
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
09
12
2021
revised:
19
01
2022
accepted:
20
01
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
ppublish
Résumé
Generally, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations are not free of side effects. A rarely reported adverse reaction to SARS-CoV-2 vaccinations is small fiber neuropathy (SFN). Here, we present three patients with SFN after the second dose of messenger ribonucleic acid-based SARS-CoV-2 vaccines. Data for this study were collected via the self-made platform "Pubbly" for reporting side effects of SARS-CoV-2 vaccinations. Three patients with post-SARS-CoV-2 vaccination SFN were identified: a 40 yo Caucasian female (patient 1), a 52 yo Caucasian female (patient 2), and a 32 yo Caucasian female (patient 3). Patient 1 complained about fatigue, dizziness, flushing, palpitations, diarrhea, muscle weakness, and gait disturbance 10 days after the second Pfizer jab. Patient 2 reported dizziness, balance problems, brain fog, palpitations, dysphagia, and sleep problems. Patient 3 complained about profound fatigue, brain fog, vertigo, pre-syncopal sensations, hair loss, chest pain, dyspnea, palpitations, paresthesias, irregular menstrual cycles, muscle weakness, and hives 1 day after the second Moderna dose. All three patients underwent skin biopsy upon which SFN was diagnosed. Patient 1 profited from immunoglobulins, but patient 2 did not require any treatment. Symptoms in patient 3 resolved upon symptomatic treatment. Despite treatment, patient 1 did not completely recover. SFN can be a rare side effect of SARS-CoV-2 vaccinations. Post-SARS-CoV-2 vaccination SFN can be mild or severe and may or may not require treatment. Post-SARS-CoV-2 vaccination SFN is most likely immune-mediated as it responds to intravenous immunoglobulins.
Identifiants
pubmed: 36387712
doi: 10.4103/jfmpc.jfmpc_2394_21
pii: JFMPC-11-4071
pmc: PMC9648331
doi:
Types de publication
Case Reports
Langues
eng
Pagination
4071-4073Informations de copyright
Copyright: © 2022 Journal of Family Medicine and Primary Care.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Ital J Dermatol Venerol. 2021 Apr;156(2):261-263
pubmed: 33034435
Neurophysiol Clin. 2021 Mar;51(2):193-196
pubmed: 33551341
Front Pharmacol. 2021 Apr 14;12:610585
pubmed: 33935704
Muscle Nerve. 2021 Jul;64(1):E1-E2
pubmed: 33851437
Clin Auton Res. 2021 Jun;31(3):385-394
pubmed: 33860871
Neurol Sci. 2021 Feb;42(2):389-397
pubmed: 33205374
Curr Neurol Neurosci Rep. 2019 Nov 26;19(12):103
pubmed: 31773305
Muscle Nerve. 2022 Jan;65(1):10-28
pubmed: 34374103
Semergen. 2020 May - Jun;46(4):277-282
pubmed: 31899152
Continuum (Minneap Minn). 2014 Oct;20(5 Peripheral Nervous System Disorders):1398-412
pubmed: 25299289
J Neurol. 2020 Dec;267(12):3499-3507
pubmed: 32613444
eNeurologicalSci. 2020 Dec;21:100276
pubmed: 32984564
J Parkinsons Dis. 2019;9(4):761-765
pubmed: 31381529
Ther Adv Neurol Disord. 2021 Mar 23;14:17562864211004318
pubmed: 34335876
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946748
Curr Opin Neurol. 2021 Oct 1;34(5):675-682
pubmed: 34392300
Korean J Pain. 2021 Oct 01;34(4):427-436
pubmed: 34593660
Vaccine. 2009 Dec 9;27(52):7322-5
pubmed: 19808027
Korean J Pain. 2018 Oct;31(4):235-243
pubmed: 30310548
Eur Neurol. 2018;80(5-6):304-310
pubmed: 30889595